生物制药公司Omeros(OMER.US)暴涨超156%，报10.51美元。 消息面上，诺和诺德公布，将斥资高达21亿美元向取得实验性罕见疾病药物的权利。Omeros将获得3.4亿美元的预付款及阶段性付款，其余款项则将与研发及商业里程碑挂钩。该实验药物扎替尼巴特(zaltenibart)正进行用于治疗罕见血液及肾脏疾病的测试。(格隆汇) 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱：news_center@staff.hexun.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.